JAMES J.

WARD
________________________________________
E-Mail: jwe578bc@westpost.net
________________________________________
EXPERIENCED SCIENTIST/PROJECT MANAGER
Accomplished scientist and leader with a proven history of success driving busin
ess results to achieve increased profitability and organizational success. Align
s departmental strategy with franchise vision and creates a cohesive, highly pro
ductive culture dedicated to the accomplishment of business objectives. Possess
es an unwavering focus on providing exceptional customer results with a global v
ision to move ideas and innovations across markets. Strengths include exceptiona
l interpersonal skills to forge internal and external relationships, and a demon
strated ability to successfully overcome challenges to consistently ensure proje
ct completion on time and within budget.
CORE COMPETENCIES
Project Management * Staff Leadership * Interdisciplinary Collaboration * Managi
ng Conflict * Staff Training & Development * Innovation * Vendor Management *Con
sumer Needs Assessment * Data Interpretation * Clinical Documentation * Pharmaco
logy * Toxicology * Quality Assurance * Wound Management * Plastic & Reconstruct
ion *Women's Health * Urology
TECHNICAL SKILLS
Windows 2007 * XP * Vista * MS-Office * Word 7.0 * Excel * Power Point * Interne
t Explorer * Statistical Analysis - SAS JMP * Jandel SigmaStat 1.0 * MiniTab 15
* Image Analysis - Image Pro * Adobe Photoshop
________________________________________
EXPERIENCE
JOHNSON & JOHNSON FAMILY OF COMPANIES 1995-2010
ETHICON, INC., Somerville, NJ 2001-2010
PRINCIPAL SCIENTIST (2007-2010)
Served as study director in the successful execution of domestic and internation
al projects in accordance with protocol and regulatory requirements. Trained and
mentored interdisciplinary staff; supported project teams in study design, prot
ocol generation, and statistics; identified and influenced key opinion leaders t
o support product development and launch.
Key Accomplishments
* Strengthened the plastic and reconstructive product pipeline by over 300%; pro
vided high quality safety and efficacy data on four projects resulting in regula
tory approval.
* Utilized project management expertise to effectively manage 15 complex project
s simultaneously. Drove rigorous schedules, maintained consistent communication
with team leaders and met or exceeded all deadlines.
* Provided valuable contributions to product safety and efficacy through extensi
ve literature reviews, proving established animal models, and generating novel i
n vivo and in vitro testing systems. Devised and implemented over 60 innovative
models predictive of clinical outcomes, with results supportive of domestic and
international regulatory submissions and approvals.
JAMES J. WARD - PAGE 2
EXPERIENCE (CONTINUED)
* Ensured global operational efficiency and compliance excellence through compre
hensive understanding of ISO, QSR, GLP, USDA, AAALAC, DEA, FDA and OSHA requirem
ents. Identified areas for improvement and proactively engaged staff in communic
ation and review of key quality procedures to ensure harmonized organizational p
rocesses relative to quality issues.
* Positively impacted the execution of an international study; effectively prese
nted the optimal cost/benefit scenario for implementation resulting proactive re
solution of potential obstacles and achievement of team buy-in.
* Elicited customer needs through the design and implementation of Voice of Cust
omer assessments in the US, Germany, and Mexico. Gathered valuable information t
o support global growth through innovation and market creation.
* Advanced organizational goals; managed the activities of six contract research
organizations (CROs) from identification through final report to successfully m
eet critical deadlines. Contributed to the essential documentation utilized by 7
0 product teams to guide a product from discovery through development.
* Established productive collaborations with academic and industry organizations
; combined scientific acumen with outstanding interpersonal skills to forge rela
tionships accelerating growth and product launch, resolving complex problems, an
d enhancing creativity.
* Spurred the development of franchise-wide scope and new growth platforms throu
gh a novel, results-driven scientific research proposal targeting myofibroplasts
as modulators for mesh contraction.
SENIOR SCIENTIST (2001-2007)
Managed scheduling, staff, and cross-functional collaborations to prioritize and
obtain accurate, timely results. Boosted the professional development of direct
reports; worked with CROs, vendors, universities, and sister franchises to achi
eve business goals.
Key Accomplishments
* Provided crucial support for the company's conversion to a highly lucrative su
ture line. Demonstrated proof of concept leading to regulatory approval of the "
Plus" antimicrobial suture line and $1B in subsequent sales.
* Developed a record of organizational achievements; filed four patents, obtaine
d FDA 510(k) approvals for 15 new devices, and designed and performed feasibilit
y, discovery and development protocols supporting projects from development thro
ugh launch.
* Leveraged process improvement expertise to streamline administrative processes
. Generated a global service agreement with contract research organizations appl
icable to all business units and collaborated with procurement to establish a ce
ntralized system for study director billing charges thus reducing departmental t
ime and resources needed to complete individual charges.
WOUND HEALING TECHNOLOGY RESOURCE CENTER, Skillman, NJ 1995-2000
STAFF SCIENTIST (1995-2001)
Liaised between Advanced Wound Care (UK), New Business Development (TX & NJ), Co
nsumer Products Worldwide (NJ) and J&J Japan (JP). Supported launch and/or claim
s support for FIBRACOL, TIELLE* Lite, ACTISORB*PLUS, REGRANEX(R), DERMABOND*, PR
OMOGRAM*, and Integra.
JAMES J. WARD - PAGE 3
EXPERIENCE (CONTINUED)
Key Accomplishments
* Led departmental innovations team achievements consisting of 23 patent applica
tions and 65 "idea" memos over a 16 month period. Filed three patents and devel
oped novel models of infection and ischemia that lead to a patent grant.
* Stepped up in the absence of department veterinarian; managed and maintained t
he productivity of the animal models and histopathology group for eight months p
ending identification of veterinary staff.
ADDITIONAL EXPERIENCE
OHMEDA PHARMACEUTICAL PRODUCTS, INC., Cardiovascular, Murray Hill, NJ
STAFF SCIENTIST, GASTROINTESTINAL DEPARTMENTS - BIOLOGICAL RESEARCH
Established a new gastrointestinal pharmacology section, implemented in vivo par
adigms resulting in nomination of a candidate drug, and independently conducted
cardiovascular safety assessments of anesthetic and motilin analogue standards a
nd investigational compounds
WYETH-AYERST RESEARCH LABORATORIES, INC., Princeton, NJ
SENIOR PHARMACOLOGIST, IMMUNOPHARMACOLOGY DIVISION - DEPARTMENT OF EXPERIMENTAL
THERAPEUTICS
Developed several successful in vivo models from published and self-created meth
ods for the assessment of novel anti-osteoarthritic compounds; prepared and perf
ormed a wide variety of surgical pharmacological assays.
PRIVATE FORMULATIONS INC., Edison, NJ
QUALITY ASSURANCE ASSISTANT
Reviewed and approved master formulas and batch records of O.T.C. drugs and vita
mins. Supervised labeling and warehousing of final products.
JOHNSON & JOHNSON BABY PRODUCTS, Skillman, NJ
LABORATORY TECHNICIAN
Participated on a special research team to study absorption aspects of investiga
tional compounds.
BIO/DYNAMICS, INC., Rodent Toxicology Department, Millstone, NJ
TECHNICIAN-IN-CHARGE
Supervised six toxicology technicians in the performance of acute and chronic to
xicology studies; reviewed and approved final report data.
EDUCATION
Master of Business Administration (in process) - STEVENS INSTITUTE OF TECHNOLOG
Y, Hoboken, NJ
Bachelor of Science in Biology - LYNCHBURG COLLEGE, Lynchburg, VA
Lean Six Sigma - Green Belt Training - Vector International, Inc.
CONTINUING EDUCATION: Organic Chemistry II, Pharmacology and Physiology - RUTGE
RS UNIVERSITY, College of Pharmacy, Piscataway, NJ

JAMES J. WARD - PAGE 4

PATENTS
US Patent No. 6250306 Ischemic Wound Model (Assessment of Ischemic Wound Healin
g Therapeutics)
Inventors: Gritsus, V., Niciporciukas, C., Iarkowski, L, Ward, J. 2000
Filed
US Patent No. 20090004253 Composite Device for the Repair or Regeneration of Ti
ssue
Inventors: Gosiewska, A., Brown, L., Pannozzo, M., Ward, J., Marsden, D. 200
9
Docket JJM0336 Novel Diabetic Swine Impaired Model (Diabetic Swine; Novel Impai
red
Wound Model.
Inventors: Niciprciukas, C., Iarkowski, L., Ward, J., Cullen, B. 1997
Docket PRB-192 Wound Infection Model.
Inventor: Ward, J. 1999
PUBLICATIONS
Ward, J., Ovington, L., Weisberg, M., Bhende, S., and Perry, L.: Comparison of M
icrobial barrier Performance and Strength of Commercially Available Topical Skin
Adhesives Under Mechanical Stress. Submitted Wound Repair and Regeneration, Sub
mitted 2010.
Storch, M, Perry, L., Davidson, J., and Ward, J.: A 28-Day Study of the Effect o
f Coated VICRYL* Plus Antibacterial Suture (Coated Polyglactin 910 Suture with T
riclosan) on Wound Healing in Guinea Pig Linear Incisional Dermal Wounds. Surgic
al Infections, Vol. 3, Supp, 2002.
Ward, J.J., Gritsus, V., Panozzo, M., Kemelgor, C., Lin, X. and Bradley, D.: A N
ovel Model of Tissue Ischemia: Surgically Formed Supported Cutaneous Flap. Wound
Repair and Regeneration, March-April 2001.
Ward, J.J., Gritsus, V., Brown, L., and Bradley, D.: A Novel Model of Tissue Isc
hemia: Surgically Formed Supported Cutaneous Flap. 7th Johnson & Johnson Worldwi
de Skin Care Symposium, June 2001.
Ward, J.J., Perry, L., Burtis, D., and Niciporciukas.M.C.: A Novel Swine Model o
f Infection. 6th Johnson & Johnson Worldwide Skin Care Symposium, June 1999.
Gritsus, V., Ward, J.J., Iarkowski, L., and Niciporciukas, M.C.: A Novel Model o
f Tissue Ischemia-Surgically Formed Supported Cutaneous Flap. 6th Johnson & John
son Worldwide Skin Care Symposium, June 1999.
Ward, J.J., Niciporciukas, M.C., and Wisniewski, S.: The Effect of Formulation V
ehicles Containing 5% Microfine Zinc Oxide on the Healing of Partial-Thickness E
xcisional Wounds Covered With Non-Medicated BABAB in Swine. 5th Johnson & Johnso
n Worldwide Skin Care Symposium, June 1977.
Macielag, M.J., Gregory, R., Deportere, I., Florance, J., Peeters, T.L., Ward, J
., Dettelback, J. and Galdes, A.: The Motilin Analog OHM-11638 Induces Phase III
-Like Contractions of the Upper Gut and Enhances Gastric Emptying in the Conscio
us Dog. Submitted Gastroenterology, December 1994.
JAMES J. WARD - PAGE 5
PUBLICATIONS (CONTINUED)
Chung, S.A., Valdez, D.T., Macielag, M.J., Gregory, R.L., Dharanipragada, R., Fl
orance, J.L., Ward, J.J., Galdes, A., and Diamant, N.E.: Phase III-Like Gastroin
testinal Motor Activity Induced by Synthetic Motilin Fragments of Different Enzy
matic Stabilities. Abstract American Motility Society 1994.
Macielag, M.J., Gregory, R.L., Peeters, T.L., Florance, J.R., Ward, J.J., Deport
ere, I., Dharanipragada, and Galdes, A.: The In Vivo GI Motor Stimulating Activi
ty of Truncated Motilin Analogs - Relationship to In Vitro Biostability. Abstrac
t 10th International Symposium on Gastrointestinal Hormones, Santa Barbara, Augu
st 1994.
Gregory, R.L., Ward, J.J., Wynn, R.L., and Dunn, R.W.: The Antiemetic Effect of
the NOS Inhibitors L-NG-Nitro-Arginine Methyl Ester (L-NAME) and L-NG-Nitro-Arg
inine (L-NOARG) in Ferrets. Gastroenterology, December 1994.
Russell, J., Ward, J., Becci, M., and Mir, G.N.: Gastric Emptying and Small Inte
stinal Motility in STZ-Diabetic Rats. Digestive Diseases and Sciences 1989.
Russell, J., Ward, J., Becci, M., and Mir, G.N.: Spontaneous Gastric Ulceration
in STZ-Diabetic Rats. Drug Development Research 1989.
Borella, L., Morrow, D., DiJoseph, J., Ward, J., Wells, C., and Nam, S.: SR Oruv
ail and Orudis Ketoprofen capsules: Comparison of effects on the Integrity of Do
g and Cat GI Mucosa Induced by Subchronic Equal Daily Treatments, Gastroenterolo
gy 1989.
Russell, J., Moss, C., Ward, J., Becci, M., and DiJoseph, J.: Effects of Rat Str
ain and Sex on Gut Ulceration. Abstract F.A.S.E.B., 1987.